<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12915868</article-id><article-id pub-id-type="pmc">2376909</article-id><article-id pub-id-type="pii">6601158</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liepe</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kropp</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Runge</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kotzerke</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Department of Nuclear Medicine, University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:liepe@rcs.urz.tu-dresden.de">liepe@rcs.urz.tu-dresden.de</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>08</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>18</day><month>08</month><year>2003</year></pub-date><volume>89</volume><issue>4</issue><fpage>625</fpage><lpage>629</lpage><history><date date-type="received"><day>05</day><month>12</month><year>2002</year></date><date date-type="rev-recd"><day>01</day><month>05</month><year>2003</year></date><date date-type="accepted"><day>25</day><month>05</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>rhenium-188-HEDP</kwd><kwd>prostate cancer</kwd><kwd>bone metastases</kwd><kwd>therapeutic efficiency</kwd></kwd-group></article-meta></front><body><p>Prostate cancer is the second common cause of cancer mortality in men in the UK and in the US (<xref ref-type="other" rid="bib1">American Cancer Society, 1991</xref>; <xref ref-type="other" rid="bib27">Office for National Statistics Series, 1996</xref>). Prostate cancer accounts for 17&#x00025; of malignant diseases in men &#x0003e;50 years in Germany (<xref ref-type="other" rid="bib15">&#x02018;Krebsregister in Deutschland&#x02019;, 1999</xref>) with a 5-year survival rate of 70&#x00025;.</p><p>The skeleton is the most common site for prostatic metastases. The major mechanism of pain from small metastases appears to be the stimulation of nerve endings in the endosteum by a variety of chemical mediators. Larger bone metastases produce stretching of the periosteum that leads to pain (<xref ref-type="other" rid="bib26">Nielsen <italic>et al</italic>, 1991</xref>). Resulting bone pain interferes with the patient's quality of life and requires effective treatment. Unfortunately, various nonradiotherapeutic modalities such as analgesics, hormone therapy, orchidectomy, cytostatic and cytotoxic drugs, bisphosphonates and surgery are not effective in all cases, especially in the late stage of the disease (<xref ref-type="other" rid="bib24">McEwan, 1998</xref>; <xref ref-type="other" rid="bib7">Debes and Tindall 2002</xref>; <xref ref-type="other" rid="bib11">Gilligan and Kantoff, 2002</xref>). External-beam radiotherapy is suitable only for well-defined localised bone metastases. Extended field radiation may be useful in patients with diffuse metastases, but is often accompanied by serious side effects (<xref ref-type="other" rid="bib17">Lewington, 1993</xref>). Therefore, systemic radionuclide therapy must be considered as a valuable and effective method of treatment in patients with widespread skeletal metastases.</p><p>The various radiopharmaceuticals that are used for palliative treatment of bone metastases include strontium-89 (<xref ref-type="other" rid="bib29">Pecher, 1942</xref>Pl. check Pecher or Pecher et al) phosphorus-32 (<xref ref-type="other" rid="bib10">Friedell and Storaassli, 1950</xref>), iodine-131-BDP3 (<xref ref-type="other" rid="bib8">Eisenhut <italic>et al</italic>, 1986</xref>), yttrium-90 (<xref ref-type="other" rid="bib16">Kutzner <italic>et al</italic>, 1991</xref>), rhenium-186-HEDP (<xref ref-type="other" rid="bib22">Maxon <italic>et al</italic>, 1990</xref>) and samarium-153-EDTMP (<xref ref-type="other" rid="bib32">Turner <italic>et al</italic>, 1989</xref>). More recently, tin-17m-DTPA (<xref ref-type="other" rid="bib2">Atkins <italic>et al</italic>, 1995</xref>) rhenium-188-HEDP (<xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic>, 2000</xref>) and rhenium-188-DMSA (<xref ref-type="other" rid="bib4">Blower <italic>et al</italic>, 2000</xref>) have been reported to be effective for bone pain palliation.</p><p>We have had more than 5 years experience in the use of <sup>188</sup>Re-HEDP for the palliative treatment of bone metastases. Rhenium-188-HEDP has a rapid renal excretion (40&#x000b1;12&#x00025; of administered activity within the first 8&#x02009;h), leading to a low radiation dose to the whole body (0.07&#x000b1;0.02&#x02009;mGy&#x02009;MBq<sup>&#x02212;1</sup>) and a relative short biological half-life (51&#x000b1;43&#x02009;h) in comparison to the half-life within bone metastases (269&#x000b1;166&#x02009;h) (<xref ref-type="other" rid="bib20">Liepe <italic>et al</italic>, 2003</xref>). The favourable physical characteristics of the radionuclide for its use in palliative therapy are a short physical half-life of 16.9&#x02009;h and a maximal <italic>&#x003b2;</italic>-energy of 2.1&#x02009;MeV with a 15&#x00025; <italic>&#x003b3;</italic>-component of 155&#x02009;keV. This <italic>&#x003b3;</italic>-component allows the control of tissue distribution after therapy. As a product from in-house <sup>188</sup>W&#x0002f;<sup>188</sup>Re generator, similar to a technetium generator, <sup>188</sup>Re-HEDP show a vantage availability. The long useful shelf-life of the generator leads to lower costs in comparison to other radiopharmaceuticals like strontium-89, rhenium-186-HEDP and samarium-153-EDTMP.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Preparation of <sup>188</sup>Re-HEDP</title><p>Rhenium-188-HEDP was prepared as previously described by <xref ref-type="other" rid="bib19">Lin <italic>et al</italic> (1997)</xref> and <xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic> (2000)</xref>. <sup>188</sup>Re-perrhenate was obtained from a 38&#x02009;GBq alumina-based <sup>188</sup>W&#x0002f;<sup>188</sup>Re generator (<xref ref-type="other" rid="bib13">Knapp <italic>et al</italic>, 1997</xref>) (Oak Ridge National Laboratory, Oak Ridge, USA). The generator was eluted with 20&#x02013;25&#x02009;ml of 0.9&#x00025; saline. The generator eluates were concentrated to about 1.2&#x02009;ml using a tandem cation&#x0002f;anion concentration system (<xref ref-type="other" rid="bib12">Guhlke <italic>et al</italic>, 2000</xref>), which consists of an Ag Plus cartridge (Alltech Associates, Deerfield, IL, USA) attached to a three-way stopcock connected at the outlet to the QMA anion trapping column SepPak&#x000ae; (Waters Corporation, Milford, MA, USA) anion-exchange column. The concentration system was housed in a Lucite shield.</p><p>In total, 8.3&#x02009;mg HEDP (Fluka Chemie AG, Buchs, Switzerland), 3.0&#x02009;mg gentisic acid (Sigma-Aldrich, Steinheim, Germany) and 3.9&#x02009;mg stannous chloride dihydrate (Merck, Darmstadt, Germany) were weighed in kit vials and mixed with 1.0&#x02009;ml of carrier-added <sup>188</sup>Re-generator eluate (10&#x02009;<italic>&#x003bc;</italic>l ReO4 Aldrich, 100&#x02009;<italic>&#x003bc;</italic>mol&#x02009;ml<sup>&#x02212;1</sup> physiological saline). The solution was heated at 96&#x02013;100&#x000b0;C for 15&#x02009;min. After cooling to room temperature, 1&#x02009;ml of a sterile 0.3&#x02009;<sc>M</sc> sodium hydroxide solution was added to adjust the pH to a range of 5&#x02013;6.</p><p>Quality control of carrier-added <sup>188</sup>Re-HEDP was performed with thin layer chromatography using silica gel (ITLC-SG) strips (Gelman, Ann Arbor, MI, USA). In addition, anion exchange chromatography based on gradient elution with increasing concentrations of NaCl solutions using a QMA SepPak&#x000ae; was used. The radiochemical purity determined by both procedures (ITLC and ion exchange) was more than 90&#x00025;. Sterility and pyrogenicity tests were performed for each preparation.</p></sec><sec><title>Patients</title><p>In this phase II study, 27 patients with multiple bone metastases from prostate cancer and pain well-controlled by conventional analgesia were included. In previous dose-escalation studies (<xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic>, 2000</xref>), an activity of 3300&#x02009;MBq of <sup>188</sup>Re-HEDP was determined as suitable for bone pain palliation. We evaluated the effect of <sup>188</sup>Re-HEDP on pain relief, reduction of analgesics and changes in quality of life. Before and for 12 weeks after the <sup>188</sup>Re-HEDP therapy, weekly interviews with a standardised set of questions concerning pain relief with the visual analogue scale (VAS) from 0 to 100&#x00025; (<xref ref-type="other" rid="bib31">Serafini <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib14">Kraeber-Bodere <italic>et al</italic>, 2000</xref>), analgesics and Karnofsky performance scale were conducted weekly (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Time course of the Karnofsky performance scale before and within 12 weeks after <sup>188</sup>Re-HEDP therapy (with s.d.'s).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601158f1"/></fig>). A pain relief &#x02a7d;25&#x00025; on the VAS at least in two consecutive weeks without increase of analgesics was used as criteria for response.</p><p>Blood counts were obtained to evaluate the impairment of bone marrow function within 6 weeks after therapy and in the 12th week. For the assessment of toxicity, the toxicity criteria of the <xref ref-type="other" rid="bib33">World Health Organization (1979)</xref> were used. According to this toxicity scale, platelet counts of 74&#x02013;99&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>, 50&#x02013;74&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>, 25&#x02013;49&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> and below 25&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> correspond to a toxicity grade of 1, 2, 3 and 4, respectively. The maximum decrease was calculated by comparison of the level of blood counts before therapy (baseline) with the lowest level within 12 weeks. All patients underwent a <sup>99m</sup>Tc-HMDP bone scan within 1 month before and 3 months after therapy to obtain a possible decrease of the mass of bone metastases. In a single case, we had also a later bone scan.</p><p>Criteria for patient inclusion in the study were
 <list list-type="bullet"><list-item><p>positive <sup>99m</sup>Tc-HMDP bone scan with at least three lesions;</p></list-item><list-item><p>bone pain symptoms requiring the long-term use of analgesics;</p></list-item><list-item><p>sufficient bone marrow function with a platelet count &#x02a7e;100 &#x000d7; 10<sup>3</sup>&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, leucocyte count &#x02a7e;3.0&#x0002a;10<sup>3</sup>&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> and haemoglobin &#x02a7e;6.0&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup> (9.67&#x02009;g&#x02009;dl<sup>&#x02212;1</sup>);</p></list-item><list-item><p>normal renal function.</p></list-item></list></p><p>Criteria for exclusion were
 <list list-type="bullet"><list-item><p>metastatic bone fractures;</p></list-item><list-item><p>spinal cord compression;</p></list-item><list-item><p>soft tissue tumours elsewhere causing nerve compression.</p></list-item></list></p><p>Chemotherapy and bisphosphonate therapy were discontinued 4 weeks before the administration of the radiopharmaceutical. In accordance with the Helsinki declaration, all patients were informed comprehensively about the study and possible side effects and were provided with a leaflet. Consent approval had been obtained from the local ethics committee.</p></sec><sec><title>Statistics</title><p>Data are presented as mean&#x000b1;s.d. For determining a significant change in the visual analogue scale and Karnofsky performance scale, we used the Student's <italic>t</italic>-test. Two-tailed <italic>P</italic>-values less than 0.05 were considered to indicate statistical significance.</p></sec></sec><sec><title>RESULTS</title><p>Twenty-seven patients (mean age&#x0003d;68, range 55&#x02013;87 years) with disseminated bone metastases from prostate cancer received a single intravenous injection of <sup>188</sup>Re-HEDP. The administered activity ranged from 2700 to 3587&#x02009;MBq (mean dose&#x0003d;3245&#x000b1;356&#x02009;MBq). All patients had analgesics. Patients were hospitalised for 2 days for the <sup>188</sup>Re-HEDP therapy due to regulations in the German radiation protection law. All patients had a single therapy. All patients received a hormone therapy for at least 6 months before therapy and also during the post-therapy observation period. Nineteen patients had been treated with a bisphosphonate for at least 6 months, this was discontinued four weeks before therapy. In addition, five patients received chemotherapy and seven patients external beam radiation prior to the <sup>188</sup>Re-HEDP therapy. All these treatments were finished at least 5 months before the <sup>188</sup>Re-HEDP therapy. It is unlikely that these various preceding therapies modified or altered the observed therapeutic effect in this study.</p><p>Twenty-five patients were included in the evaluation of the therapeutic efficiency of the <sup>188</sup>Re-HEDP therapy. Two patients were excluded: one patient because of incomplete follow-up and one died 9 weeks after treatment from the cancer, unrelated to the therapy.</p><p>The Karnofsky performance scale increased from 74&#x000b1;7&#x00025; before therapy to 85&#x000b1;9&#x00025; at 12 weeks after therapy (<xref ref-type="fig" rid="fig1">Figure 1</xref>). This increase was statistically significant (<italic>P</italic>&#x0003d;0.001). Pain relief &#x02a7d;25&#x00025; on the VAS at least in two consecutive weeks without increase of analgesics intake was achieved in 76&#x00025; of patients (19 out of 25). Five from these 19 patients were pain free (20&#x00025;). The VAS showed a decrease from 44&#x000b1;18 to 31&#x000b1;25&#x00025; at the 12th week after <sup>188</sup>Re-HEDP therapy (<italic>P</italic>&#x0003d;0.009) (<xref ref-type="fig" rid="fig2">Figure 2</xref><fig id="fig2"><label>Figure 2</label><caption><p>Time course of the pain at visual analogue scale before and within 12 weeks after <sup>188</sup>Re-HEDP therapy (with s.d.'s).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601158f2"/></fig>). The maximum of pain relief was described within the 3rd to the 8th week (27&#x000b1;20&#x00025;).</p><p>There was no evidence of either local or systemic intolerance to treatment with <sup>188</sup>Re-HEDP, while a flare reaction with an increase of pain within 14 days after therapy was noted in 16&#x00025; of patients. Most of the patients showed a grade I anaemia according to the WHO criteria (<xref ref-type="other" rid="bib33">World Health Organization, 1979</xref>) before injection, with no significant worsening within 12 weeks after therapy (haemoglobin 7.6&#x000b1;2.6 before and 7.1&#x000b1;3.0&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup> 12 weeks after treatment). The maximum decrease in one patient from the baseline value was 6.8 to 5.7&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup>. There was mild thrombocytopaenia (grade I thrombocytopaenia in two patients and grade II in one patient), but no evidence of unacceptable toxicity (defined as grade III or IV toxicity). Thrombocytopaenia was reversible within 12 weeks after therapy. The platelet counts decreased from a baseline value of 286&#x000b1;75&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> to a maximum of 218&#x000b1;83&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> at 2.7&#x000b1;0.9 weeks after therapy (<xref ref-type="fig" rid="fig3">Figure 3</xref><fig id="fig3"><label>Figure 3</label><caption><p>Bone marrow impairment due to <sup>188</sup>Re-HEDP expressed as platelet counts in serial blood samples (with s.d.'s).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601158f3"/></fig>). The patient with a thrombocytopaenia grade II had a platelet count of 62&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>. Grade I leucopenia was observed only in one patient (2.9&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>) and was also reversible within 12 weeks. The leucocyte counts decreased from a baseline value of 7.4&#x000b1;1.5&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>&#x02013;6.0&#x000b1;1.9&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> at 3.0&#x000b1;0.6 weeks after therapy (<xref ref-type="fig" rid="fig4">Figure 4</xref><fig id="fig4"><label>Figure 4</label><caption><p>Bone marrow impairment due to <sup>188</sup>Re-HEDP expressed as leucocyte counts in serial blood samples (with s.d.'s).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601158f4"/></fig>).</p><p>Generally, over the follow-up period, there were no significant changes in the PSA levels, but in individual cases a decrease was noted (PSA level: 159&#x000b1;151 <italic>vs</italic> 155&#x000b1;203&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>; <italic>P</italic>&#x0003d;0.96).</p><p>No patient showed a decrease in the bone metastases demonstrated on the <sup>99m</sup>Tc-HMDP bone scans before treatment when compared to the scans obtained 3 months post-treatment. The bone scan index (BSI) level (<xref ref-type="other" rid="bib3">Blake <italic>et al</italic>, 1986</xref>) in the group of patients with no response to the <sup>188</sup>Re-HEDP therapy was 54&#x000b1;19, in the group of patients with a good response 37&#x000b1;14 and in pain-free patients 36&#x000b1;5 (<italic>P</italic>&#x0003d;0.24). In three of the patients, there was a decrease of the number of bone metastases with a mean decrease of the BSI level from 33&#x000b1;18 before treatment to 19&#x000b1;11 within 1 year after <sup>188</sup>Re-HEDP therapy. One of these showed an improvement of the BSI from 45 to 17 six months after therapy (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref><fig id="fig5"><label>Figure 5</label><caption><p>(<bold>A</bold>) Bone scan of a 71-year-old patient with bone metastases induced by prostate cancer one month before <sup>188</sup>Re-HEDP therapy (bone scan index&#x0003d;45). The Karnofsky performance scale was 70&#x00025; and the pain of the visual analogue scale&#x0003d;50&#x00025;. (<bold>B</bold>) Bone scan of the same patient 6 months after therapy (bone scan index&#x0003d;17). The Karnofsky performance scale was 80&#x00025; and the pain of the visual analogue scale&#x0003d;25&#x00025;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601158f5"/></fig>). The 71-year-old patient was treated by bisphosphonate therapy (with etidronacid), nonsteroid antiandrogen (flutimide), progestagen (megestrolacetate) and an analogue of the luteinising hormone (goserelineacetate) from the beginning of the disease. Under this therapy, the patient described a progression of the disease with an increase in pain symptoms. Within 12 weeks of the <sup>188</sup>Re-HEDP therapy, the Karnofsky performance scale increased from 70 to 80&#x00025;, and the pain at the VAS decreased from 50 to 25&#x00025;.</p></sec><sec><title>DISCUSSION</title><p>Systemic radionuclide therapy with <italic>&#x003b2;</italic>-emitting radiopharmaceuticals represents a therapeutic option in the management of intractable metastatic bone pain and has been used since 1942 (<xref ref-type="other" rid="bib29">Pecher, 1942</xref>). Nowadays, strontium-89, rhenium-186-HEDP and samarium-153-EDTMP are the preferred radiopharmaceuticals. From a theoretical point of view, <sup>188</sup>Re-HEDP offers potential as a new and attractive radiopharmaceutical for the treatment. As a generator product it has an excellent availability that permits on-site labelling as with the routinely used <sup>99m</sup>Tc-generator resulting in low costs.</p><p>In the literature there are few reports about the therapeutic efficiency of <sup>188</sup>Re-HEDP in only small patient groups (<xref ref-type="other" rid="bib23">Maxon <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic>, 2000</xref>), which reported a response rate of 70&#x02013;80&#x00025;. In 23 patients with bone metastases from a variety of primary tumours, <sup>188</sup>Re-HEDP therapy was able to reduce analgesic intake in 82&#x00025; of patients (<xref ref-type="other" rid="bib5">Chen, 2000</xref>). In addition, 70&#x00025; of the patients had a significant and 22&#x00025; a minor improvement of quality of life. Using <sup>188</sup>Re-HEDP at an activity of 1100&#x02009;MBq, a response rate of 80&#x00025; was obtained in a cohort of 61 patients with various primary tumours (<xref ref-type="other" rid="bib18">Li <italic>et al</italic>, 2001</xref>). Studies with a large number of patients exist for patients treated with strontium-89, rhenium-186-HEDP and samarium-153-EDTMP. In a multicentre study with 818 patients treated with strontium-89 and rhenium-186-HEDP <xref ref-type="other" rid="bib6">Dafermou <italic>et al</italic> (2001)</xref> described pain relief in 81&#x00025; of the patients with prostate cancer and 27&#x00025; of these were pain free. <xref ref-type="other" rid="bib9">Enrique <italic>et al</italic> (2002)</xref>showed a response rate of 73&#x00025; in a cohort of 417 patients treated with samarium-153-EDTMP at an activity varying between 18.5 and 55&#x02009;MBq&#x02009;kg<sup>&#x02212;1</sup> body weight. In our study using <sup>188</sup>Re-HEDP, pain relief was demonstrated in 76&#x00025; of patients and 20&#x00025; from these were pain free without increase of analgesia. In addition, a significant increase of the Karnofsky performance scale of 11&#x00025; compared to the initial value within 12 weeks was observed. In comparison, the dose-escalation study in a small number of patients (<italic>n</italic>&#x0003d;6) using 3300&#x02009;MBq of <sup>188</sup>Re-HEDP (<xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic>, 2000</xref>) showed a lower response rate.</p><p>In the present study, no unacceptable toxicity was observed. There were two patients with thrombocytopaenia grade I and one with thrombocytopaenia grade II. A mean decrease of platelet counts of 30&#x000b1;14&#x00025; from the baseline value was noticed, maximally at 2.7&#x000b1;0.9 weeks after therapy. The maximum decrease in one patient was down to 62&#x0002a;10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>. The leucocyte counts showed a mean decrease of 25&#x000b1;17&#x00025; from the baseline value (<xref ref-type="fig" rid="fig4">Figure 4</xref>) with a maximum at 3.0&#x000b1;0.6 weeks. Only one patient had a leucopenia grade I. The bone marrow toxicity of <sup>188</sup>Re-HEDP showed no correlation to the extension of bone metastases in the <sup>99m</sup>Tc-HMDP bone scan or the level of the BSI. Similar results are shown in the dose-escalation study with 3300&#x02009;MBq <sup>188</sup>Re-HEDP of <xref ref-type="other" rid="bib28">Palmedo <italic>et al</italic> (2000)</xref>, who observed two patients with thrombocytopaenia grade I and one with grade II. In the group with 4400&#x02009;MBq, an unacceptable toxicity was observed in three out of eight patients, two with thrombocytopaenia grade IV and one with thrombocytopaenia grade III. Therefore, an activity of 3300&#x02009;MBq of <sup>188</sup>Re-HEDP is generally accepted in the palliative treatment of bone metastases.</p><p>The mean PSA level was unchanged during the follow-up (159&#x000b1;151 <italic>vs</italic> 155&#x000b1;203&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>; <italic>P</italic>&#x0003d;0.96, but in individual cases there was a measurable decrease in the PSA.</p><p>While radionuclide therapy for bone pain is mainly palliative, occasionally cure can be obtained and in the three cases described in this study there were decreases in bone metastases shown on conventional <sup>99m</sup>Tc-HMDP bone scan with concomitant decrease in the BSI level from 33&#x000b1;18 to 19&#x000b1;11 within 1 year after treatment (<xref ref-type="other" rid="bib30">Robinson <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib25">Mertens <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib21">Liepe <italic>et al</italic>, 2000</xref>). Of these patients, two were pain free.</p><p>In general, large bone metastases demonstrated on the <sup>99m</sup>Tc-HMDP bone scans correlate well with sites of pain. In patients where there was no response to therapy, a higher BSI level was seen (BSI&#x0003d;51&#x000b1;19) compared to those patients where a favourable response occurred or the patients were pain free (BSI&#x0003d;33&#x000b1;11) (<italic>P</italic>&#x0003d;0.08). Other authors also described a higher response rate to treatment in early bone metastases, favouring active treatment in such cases (<xref ref-type="other" rid="bib14">Kraeber-Bodere <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib6">Dafermou <italic>et al</italic>, 2001</xref>).</p><p>A previous dosimetry study gave the radiation absorbed dose for <sup>188</sup>Re-HEDP as 11.8&#x000b1;6.2&#x02009;Gy (range: 1.2&#x02013;31.3&#x02009;Gy) for the bone metastases, and 1.9&#x000b1;0.7&#x02009;Gy (1.3&#x02013;3.6&#x02009;Gy) for the red bone marrow (<xref ref-type="other" rid="bib20">Liepe <italic>et al</italic>, 2003</xref>). These values are comparable with the dosimetry for <sup>186</sup>Re-HEDP (26&#x02009;Gy for the bone metastases and 1.8&#x02009;Gy for the red bone marrow) and also with the therapeutic effect and the bone marrow toxicity of <sup>186</sup>Re-HEDP (<xref ref-type="other" rid="bib22">Maxon <italic>et al</italic>, 1990</xref>,<xref ref-type="other" rid="bib23">1998</xref>).</p><p>In conclusion, <sup>188</sup>Re-HEDP is effective in the palliation of metastatic bone pain, without induction of severe side effects.</p></sec></body><back><ack><p>The research at the Oak Ridge National Laboratory (ORNL) was supported by the US Department of Energy (DOE), under contract DE-AC05-00OR22725 with UT-Battelle, LLC.</p></ack><ref-list><ref id="bib1"><citation citation-type="book"><person-group person-group-type="author"><collab>American Cancer Society</collab></person-group><article-title/><source>Cancer Facts and Figures &#x02013; 1991</source><year>1991</year><publisher-name>Atlanta, GA: ACS</publisher-name><fpage>5</fpage>P</citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>HL</given-names></name><name><surname>Mausner</surname><given-names>LF</given-names></name><name><surname>Srivastava</surname><given-names>SC</given-names></name><name><surname>Meiken</surname><given-names>GE</given-names></name><name><surname>Cabahug</surname><given-names>CJ</given-names></name><name><surname>D'Alessandro</surname><given-names>T</given-names></name></person-group><article-title>Tin-117m(&#x0002b;4)-DTPA for palliation of pain from osseous metastases: a pilot study</article-title><source>J Nucl Med</source><year>1995</year><volume>36</volume><fpage>725</fpage><lpage>729</lpage><!--PubMed citation query: 'J Nucl Med||36|725||bib2|'--><pub-id pub-id-type="pmid">7537804</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>GM</given-names></name><name><surname>Zivanovic</surname><given-names>MA</given-names></name><name><surname>McEwan</surname><given-names>AJ</given-names></name><name><surname>Ackery</surname><given-names>DM</given-names></name></person-group><article-title>Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate</article-title><source>Eur J Nucl Med</source><year>1986</year><volume>12</volume><fpage>447</fpage><lpage>454</lpage><!--PubMed citation query: 'Eur J Nucl Med||12|447||bib3|'--><pub-id pub-id-type="pmid">3102236</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blower</surname><given-names>PJ</given-names></name><name><surname>Kettle</surname><given-names>AG</given-names></name><name><surname>O'Doherty</surname><given-names>MJ</given-names></name><name><surname>Coakley</surname><given-names>AJ</given-names></name><name><surname>Knapp</surname><given-names>FF</given-names><suffix>Jr</suffix></name></person-group><article-title><sup>99m</sup>Tc(V)DMSA quantitatively predicts <sup>188</sup>Re(V)DMSA distribution in patients with prostate cancer metastatic to bone</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><fpage>1405</fpage><lpage>1409</lpage><!--PubMed citation query: 'Eur J Nucl Med||27|1405||bib4|'--><pub-id pub-id-type="pmid">11007525</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SL</given-names></name></person-group><article-title>Treatment of metastatic bone pain with <sup>188</sup>Re-HEDP</article-title><source>J Nucl Med</source><year>2000</year><volume>5</volume><supplement>Suppl</supplement><fpage>265</fpage><!--PubMed citation query: 'J Nucl Med||5|265||bib5|'--></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dafermou</surname><given-names>A</given-names></name><name><surname>Colamussi</surname><given-names>P</given-names></name><name><surname>Giganti</surname><given-names>M</given-names></name><name><surname>Cittani</surname><given-names>C</given-names></name><name><surname>Bestagno</surname><given-names>M</given-names></name><name><surname>Piffanelli</surname><given-names>A</given-names></name></person-group><article-title>A multicentre observation study of radionuclide therapy in patients with painful bone metastases of prostate cancer</article-title><source>Eur J Nucl Med</source><year>2001</year><volume>28</volume><fpage>788</fpage><lpage>798</lpage><!--PubMed citation query: 'Eur J Nucl Med||28|788||bib6|'--><pub-id pub-id-type="pmid">11504074</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Debes</surname><given-names>JD</given-names></name><name><surname>Tindall</surname><given-names>DJ</given-names></name></person-group><article-title>The role of androgens and the androgen receptor in prostate cancer</article-title><source>Cancer Lett</source><year>2002</year><volume>187</volume><fpage>1</fpage><lpage>7</lpage><!--PubMed citation query: 'Cancer Lett||187|1||bib7|'--><pub-id pub-id-type="pmid">12359344</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisenhut</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>P</given-names></name><name><surname>Kimmig</surname><given-names>B</given-names></name><name><surname>Wingen</surname><given-names>F</given-names></name><name><surname>Krempen</surname><given-names>B</given-names></name></person-group><article-title>Iodine-131-labeled diphosphonate for the palliative treatment of bone metastases</article-title><source>Appl Radiat Isot</source><year>1986</year><volume>37</volume><fpage>741</fpage><lpage>747</lpage><!--PubMed citation query: 'Appl Radiat Isot||37|741||bib8|'--></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enrique</surname><given-names>O</given-names></name><name><surname>Zhonyun</surname><given-names>P</given-names></name><name><surname>Prma</surname><given-names>EP</given-names></name><name><surname>Pusuwan</surname><given-names>P</given-names></name><name><surname>Riccabona</surname><given-names>G</given-names></name><name><surname>Tian</surname><given-names>J-H</given-names></name><name><surname>Obaldo</surname><given-names>J</given-names></name><name><surname>Padhy</surname><given-names>AK</given-names></name></person-group><article-title>Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases</article-title><source>World J Nucl Med</source><year>2002</year><volume>1</volume><fpage>29</fpage><lpage>34</lpage><!--PubMed citation query: 'World J Nucl Med||1|29||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedell</surname><given-names>HL</given-names></name><name><surname>Storaassli</surname><given-names>JP</given-names></name></person-group><article-title>The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastasis in bone</article-title><source>AJR</source><year>1950</year><volume>64</volume><fpage>559</fpage><lpage>575</lpage><!--PubMed citation query: 'AJR||64|559||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilligan</surname><given-names>T</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name></person-group><article-title>Chemotherapy for prostate cancer</article-title><source>Urology</source><year>2002</year><volume>60</volume><fpage>94</fpage><lpage>100</lpage><!--PubMed citation query: 'Urology||60|94||bib11|'--><pub-id pub-id-type="pmid">12231060</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guhlke</surname><given-names>S</given-names></name><name><surname>Beets</surname><given-names>AL</given-names></name><name><surname>Oetjen</surname><given-names>K</given-names></name><name><surname>Mirzadeh</surname><given-names>S</given-names></name><name><surname>Biersack</surname><given-names>HJ</given-names></name><name><surname>Knapp</surname><given-names>FF</given-names></name></person-group><article-title>Simple new method for effective concentration of <sup>188</sup>Re solutions from alumina-based <sup>188</sup>W-<sup>188</sup>Re-generator</article-title><source>J Nucl Med</source><year>2000</year><volume>41</volume><fpage>1271</fpage><lpage>1278</lpage><!--PubMed citation query: 'J Nucl Med||41|1271||bib12|'--><pub-id pub-id-type="pmid">10914921</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>FF</given-names><suffix>Jr</suffix></name><name><surname>Beets</surname><given-names>AL</given-names></name><name><surname>Guhlke</surname><given-names>S</given-names></name><name><surname>Zamora</surname><given-names>PO</given-names></name><name><surname>Bender</surname><given-names>H</given-names></name><name><surname>Palmedo</surname><given-names>A</given-names></name><name><surname>Biersack</surname><given-names>HJ</given-names></name></person-group><article-title>Development of the alumina-based tungsten-188&#x0002f;rhenium-188 generator and use of rhenium-188-labeled radiopharmaceutical for cancer treatment</article-title><source>Anticancer Res</source><year>1997</year><volume>17</volume><fpage>1783</fpage><lpage>1796</lpage><!--PubMed citation query: 'Anticancer Res||17|1783||bib13|'--><pub-id pub-id-type="pmid">9179235</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraeber-Bodere</surname><given-names>F</given-names></name><name><surname>Campion</surname><given-names>L</given-names></name><name><surname>Rousseau</surname><given-names>C</given-names></name><name><surname>Bourdin</surname><given-names>S</given-names></name><name><surname>Chatal</surname><given-names>JF</given-names></name><name><surname>Resche</surname><given-names>I</given-names></name></person-group><article-title>Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><fpage>1487</fpage><lpage>1493</lpage><!--PubMed citation query: 'Eur J Nucl Med||27|1487||bib14|'--><pub-id pub-id-type="pmid">11083537</pub-id></citation></ref><ref id="bib15"><citation citation-type="book"><person-group person-group-type="author"><collab>Krebsregister in Deutschland</collab></person-group><article-title/><source>Cancer in Germany</source><year>1999</year><publisher-name>Robert Koch Institute. Saarbr&#x000fc;cken, Germany</publisher-name></citation></ref><ref id="bib16"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kutzner</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>K</given-names></name><name><surname>Grimm</surname><given-names>W</given-names></name><name><surname>Brod</surname><given-names>K</given-names></name><name><surname>R&#x000f6;sler</surname><given-names>HP</given-names></name></person-group><article-title>Treatment of bone metastases of the prostate with yttrium isotope</article-title><source>Radionuclides for Prostatic Gland</source><year>1991</year><publisher-name>Rome</publisher-name><fpage>171</fpage><lpage>183</lpage>Limouris G, Shukla SK (eds.) pp</citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewington</surname><given-names>VJ</given-names></name></person-group><article-title>Targeted radionuclide therapy for bone metastases</article-title><source>Eur J Nucl Med</source><year>1993</year><volume>20</volume><fpage>66</fpage><lpage>74</lpage><!--PubMed citation query: 'Eur J Nucl Med||20|66||bib17|'--><pub-id pub-id-type="pmid">7678397</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name></person-group><article-title>Rhenium-188 HEDP to treat painful bone metastases</article-title><source>Clin Nucl Med</source><year>2001</year><volume>26</volume><fpage>919</fpage><lpage>922</lpage><!--PubMed citation query: 'Clin Nucl Med||26|919||bib18|'--><pub-id pub-id-type="pmid">11595844</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>S</given-names></name><name><surname>Hsieh</surname><given-names>B</given-names></name><name><surname>Tsai</surname><given-names>Z</given-names></name><name><surname>Ting</surname><given-names>G</given-names></name><name><surname>Yen</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Knapp</surname><given-names>FF</given-names></name><name><surname>Stabin</surname><given-names>M</given-names></name></person-group><article-title>Rhenium-188 HEDP: a new generator-produced radio-therapeutic drug of potential value for treatment of bone metastases</article-title><source>Eur J Nucl Med</source><year>1997</year><volume>24</volume><fpage>590</fpage><lpage>595</lpage><!--PubMed citation query: 'Eur J Nucl Med||24|590||bib19|'--><pub-id pub-id-type="pmid">9169563</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liepe</surname><given-names>K</given-names></name><name><surname>Hliscs</surname><given-names>R</given-names></name><name><surname>Kropp</surname><given-names>J</given-names></name><name><surname>Runge</surname><given-names>R</given-names></name><name><surname>Knapp</surname><given-names>FF</given-names><suffix>Jr</suffix></name><name><surname>Franke</surname><given-names>WG</given-names></name></person-group><article-title>Dosimetry of <sup>188</sup>Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases</article-title><source>J Nucl Med</source><year>2003</year><volume>44</volume><fpage>953</fpage><lpage>960</lpage><!--PubMed citation query: 'J Nucl Med||44|953||bib20|'--><pub-id pub-id-type="pmid">12791825</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liepe</surname><given-names>K</given-names></name><name><surname>Kropp</surname><given-names>J</given-names></name><name><surname>Hliscs</surname><given-names>R</given-names></name><name><surname>Franke</surname><given-names>WG</given-names></name></person-group><article-title>Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy</article-title><source>Clin Nucl Med</source><year>2000</year><volume>25</volume><fpage>1</fpage><lpage>4</lpage><!--PubMed citation query: 'Clin Nucl Med||25|1||bib21|'--><pub-id pub-id-type="pmid">10634521</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maxon</surname><given-names>HR</given-names></name><name><surname>Schroder</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name></person-group><article-title>Re-186(<italic>Sn</italic>)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer</article-title><source>Radiology</source><year>1990</year><volume>176</volume><fpage>155</fpage><lpage>159</lpage><!--PubMed citation query: 'Radiology||176|155||bib22|'--><pub-id pub-id-type="pmid">1693784</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maxon</surname><given-names>HR</given-names></name><name><surname>Schroder</surname><given-names>LE</given-names></name><name><surname>Washburn</surname><given-names>LC</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Samaratunga</surname><given-names>RC</given-names></name><name><surname>Biniakiewicz</surname><given-names>D</given-names></name><name><surname>Moulton</surname><given-names>JS</given-names></name><name><surname>Cummings</surname><given-names>D</given-names></name><name><surname>Ehrhardt</surname><given-names>GJ</given-names></name><name><surname>Morris</surname><given-names>V</given-names></name></person-group><article-title>Rhenium-188(Sn)HEDP for treatment of osseous metastases</article-title><source>J Nucl Med</source><year>1998</year><volume>39</volume><supplement>4</supplement><fpage>659</fpage><lpage>663</lpage><!--PubMed citation query: 'J Nucl Med||39|659||bib23|'--><pub-id pub-id-type="pmid">9544677</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McEwan</surname><given-names>AJ</given-names></name></person-group><article-title>Palliative therapy with bone seeking radiopharmaceuticals</article-title><source>Cancer Biother Radiopharm</source><year>1998</year><volume>13</volume><fpage>413</fpage><lpage>426</lpage><!--PubMed citation query: 'Cancer Biother Radiopharm||13|413||bib24|'--><pub-id pub-id-type="pmid">10851434</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>WC</given-names></name><name><surname>Porter</surname><given-names>AT</given-names></name><name><surname>Reid</surname><given-names>RH</given-names></name><name><surname>Powe</surname><given-names>JE</given-names></name></person-group><article-title>Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report</article-title><source>J Nucl Med</source><year>1992</year><volume>33</volume><fpage>1437</fpage><lpage>1443</lpage><!--PubMed citation query: 'J Nucl Med||33|1437||bib25|'--><pub-id pub-id-type="pmid">1634933</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>OS</given-names></name><name><surname>Munro</surname><given-names>AJ</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name></person-group><article-title>Bone metastases: pathophysiology and management policy</article-title><source>J Clin Oncol</source><year>1991</year><volume>9</volume><fpage>509</fpage><lpage>524</lpage><!--PubMed citation query: 'J Clin Oncol||9|509||bib26|'--><pub-id pub-id-type="pmid">1705581</pub-id></citation></ref><ref id="bib27"><citation citation-type="book"><person-group person-group-type="author"><collab>Office for National Statistics Series DH. No 23</collab></person-group><article-title/><source>Mortalitiy Statistics by Cause: England and Wales 1996</source><year>1996</year><publisher-name>London, UK: Her Majesty's Stationary Office</publisher-name></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmedo</surname><given-names>H</given-names></name><name><surname>Guhlke</surname><given-names>S</given-names></name><name><surname>Bender</surname><given-names>H</given-names></name><name><surname>Sartor</surname><given-names>J</given-names></name><name><surname>Schoeneich</surname><given-names>G</given-names></name><name><surname>Risse</surname><given-names>J</given-names></name><name><surname>Grunwald</surname><given-names>F</given-names></name><name><surname>Knapp</surname><given-names>FF</given-names><suffix>Jr</suffix></name><name><surname>Biersack</surname><given-names>HJ</given-names></name></person-group><article-title>Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><supplement>2</supplement><fpage>123</fpage><lpage>130</lpage><!--PubMed citation query: 'Eur J Nucl Med||27|123||bib28|'--><pub-id pub-id-type="pmid">10755716</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pecher</surname><given-names>P</given-names></name></person-group><article-title>Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer</article-title><source>Univ Calif Publ Pharmacology</source><year>1942</year><volume>2</volume><fpage>117</fpage><lpage>149</lpage><!--PubMed citation query: 'Univ Calif Publ Pharmacology||2|117||bib29|'--></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>G</given-names></name><name><surname>Blake</surname><given-names>G</given-names></name><name><surname>Preston</surname><given-names>DF</given-names></name><name><surname>McEwan</surname><given-names>A</given-names></name><name><surname>Spicer</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>N</given-names></name><name><surname>Wegst</surname><given-names>A</given-names></name><name><surname>Ackery</surname><given-names>D</given-names></name></person-group><article-title>Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone</article-title><source>Radiographics</source><year>1989</year><volume>9</volume><fpage>271</fpage><lpage>281</lpage><!--PubMed citation query: 'Radiographics||9|271||bib30|'--><pub-id pub-id-type="pmid">2467331</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>AN</given-names></name><name><surname>Houston</surname><given-names>SJ</given-names></name><name><surname>Resche</surname><given-names>I</given-names></name><name><surname>Quick</surname><given-names>DP</given-names></name><name><surname>Grund</surname><given-names>FM</given-names></name><name><surname>Ell</surname><given-names>PJ</given-names></name><name><surname>Bertrand</surname><given-names>A</given-names></name><name><surname>Ahrnmann</surname><given-names>FR</given-names></name><name><surname>Orihuela</surname><given-names>E</given-names></name><name><surname>Reid</surname><given-names>RH</given-names></name><name><surname>Lerski</surname><given-names>RA</given-names></name><name><surname>Collier</surname><given-names>BD</given-names></name><name><surname>Mckillop</surname><given-names>JH</given-names></name><name><surname>Purnell</surname><given-names>GL</given-names></name><name><surname>Pecking</surname><given-names>AP</given-names></name><name><surname>Thomas</surname><given-names>FD</given-names></name><name><surname>Harrison</surname><given-names>KA</given-names></name></person-group><article-title>Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>1574</fpage><lpage>1581</lpage><!--PubMed citation query: 'J Clin Oncol||16|1574||bib31|'--><pub-id pub-id-type="pmid">9552068</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>JH</given-names></name><name><surname>Claringbold</surname><given-names>PG</given-names></name><name><surname>Hetherington</surname><given-names>EL</given-names></name><name><surname>Sorby</surname><given-names>P</given-names></name><name><surname>Martindale</surname><given-names>AA</given-names></name></person-group><article-title>A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1926</fpage><lpage>1931</lpage><!--PubMed citation query: 'J Clin Oncol||7|1926||bib32|'--><pub-id pub-id-type="pmid">2585026</pub-id></citation></ref><ref id="bib33"><citation citation-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title/><source>WHO Handbook for Reporting Results of Cancer Treatment</source><year>1979</year><publisher-name>Geneve, Switzerland: World Health Organization, Offset publication 48</publisher-name></citation></ref></ref-list></back></article>


